Christy Rossi: Sure. Thanks, Ami. So as we said before, what physicians are looking at is the consistency and totality of the data. When we look at sort of change in individual symptoms, again, the TSS is a new endpoint. It’s not used in clinical practice. The lens that I think physicians are interpreting this data through is to say, one, whatever my symptom – whatever symptom my patient is suffering from, do you have confidence that AYVAKIT will improve their quality of life and improve those symptoms? And so I think what we’ve heard is that what physicians are looking for is consistency of improvement across individual symptoms. I think looking at that longitudinally over time is going to be interesting as well. And then importantly, addressing a patient’s most bothersome symptom because we know that these patients are heterogeneous as you say and what specific symptom may be most impactful to a patient is going to be different from patient-to-patient.
And so I think what is compelling about AYVAKIT is that we do see consistent impacts and we know that regardless of the specific presentation of a patient symptomatology, we’re confident that, that patient will benefit. And I think that’s the ones that the prescribers will be looking at this data set through as well.
Ami Fadia: Thank you.
Operator: Our next question today comes from Matt Biegler from Oppenheimer. Your line is now open.
Matt Biegler: Hey, guys. Thanks for squeezing me in. I wanted to ask about median duration on therapy in ASM. If you can comment on that, is it getting longer or shorter and I guess that would be indicative of the severity of patients you’re treating and whether you’re making inroads into that agents component? Thanks.
Kate Haviland: Yeah. Thanks so much for the question. And Philina, do you want to take that?
Philina Lee: Yeah, so our median duration of therapy is trending towards 18 months. We’re highly encouraged that this is standing up well in clinical practice. And certainly, as we shift towards a mix of more treatment-naive patients, we expect that over time to increase.
Matt Biegler: Thank you.
Operator: Our final question comes from Chris Raymond from Piper Sandler. Your line is now open.
Nicole Gabreski: Good morning. This is Nicole Gabreski on for Chris. Thanks for squeezing us in. So I guess we were just wondering, of those 400 moderate your ISM patients that you had referenced, just given the experience of AYVA with those providers, are any of those patients currently receiving drug off label? And also sorry if I missed it, but would you be in a position to provide updated 2023 AYVAKIT guidance that includes ISM revenues potentially later this year post approval?
Kate Haviland: Yeah, thank you very much for that question. So starting with – I’ll answer knowing that we’re coming up against time here. But the 400 patients are really not being treated today with AYVA. We see small number of patients with ISM who are being treated, but it’s not substantial relative to our overall number of patients being treated. And then as we talk about guidance, I mean, I think our goal today is to align on where our current business stands with our approved indications of advanced SM and GIST. And to really set that foundation for all of us as we move towards this anticipated launch. And in any given launch, there are uncertainties, including what our label will look like as we go through the FDA negotiation process and how the first few months will play out. So we look forward to working with all of you as we move into this really exciting launch. So thank you very much for that.
Nicole Gabreski: Yeah. That’s all. Thanks.
Operator: That concludes the Q&A portion of today’s call. I’ll now hand back over to Kate Haviland for closing remarks.
